Iron deficiency anaemia therapeutic - Fe3 Medical
Latest Information Update: 08 Jul 2016
At a glance
- Originator Fe3 Medical
- Class Antianaemics; Iron compounds
- Mechanism of Action Iron replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Iron deficiency anaemia
Most Recent Events
- 02 Mar 2016 Preclinical trials in Iron deficiency anaemia in USA (Transdermal)